Real-World Adherence and Persistence to Emicizumab Using a National US Claims Database
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-199645
Abstract: Introduction: Emicizumab is the first bispecific factor IXa- and factor X-directed antibody approved in the US for routine prophylaxis in adult and pediatric people with hemophilia A (PwHA) with or without factor VIII (FVIII) inhibitors.… read more here.
Keywords: real world; adherence; world adherence; pwha ... See more keywords